NCT00093353 2026-04-14
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
Clinical Trials
6 trialsNCT02596503 2022-02-15
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
University of Colorado, Denver
Phase 1 Completed
NCT00786669 2021-02-10
VITAC
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed
NCT00644696 2017-07-06
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT00186979 2017-04-26
Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00004216 2013-07-18
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
Phase 1 Completed